Edivoxetine

Edivoxetine

Clinical data
ATC code	None
Legal status
Legal status	Development terminated
Identifiers
IUPAC name (1R)-2-(5-fluoro-2-methoxyphenyl)-1-[(2S)-morpholin-2-yl]-1-(tetrahydro-2H-pyran-4-yl)ethanol
CAS Number	1194508-25-2 1194374-05-4 (hydrochloride)
PubChem CID	11186829
ChemSpider	9361913
UNII	3W9N3F4JOO
KEGG	D09890
CompTox Dashboard (EPA)	DTXSID70152464
Chemical and physical data
Formula	C18H26FNO4
Molar mass	339.407 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC1=C(C=C(C=C1)F)C[C@]([C@@H]2CNCCO2)(C3CCOCC3)O
InChI InChI=1S/C18H26FNO4/c1-22-16-3-2-15(19)10-13(16)11-18(21,14-4-7-23-8-5-14)17-12-20-6-9-24-17/h2-3,10,14,17,20-21H,4-9,11-12H2,1H3/t17-,18+/m0/s1 Key:CPBHSHYQQLFAPW-ZWKOTPCHSA-N

Edivoxetine (INN; code name LY-2216684) is a drug which acts as a selective norepinephrine reuptake inhibitor and was under development by Eli Lilly for attention-deficit disorder (ADD) and as an antidepressant treatment. It was in phase III clinical trials, in 2012, for major depressive disorder, but failed to get approval.

Effectiveness

In a study published in 2010, edivoxetine succeeded to prove superiority over placebo, as measured by Hamilton Depression Rating Scale. However, effectiveness could be observed using the Self-Rated Quick Inventory of Depressive Symptomatology.

In a study published in 2011, using the Montgomery–Åsberg Depression Rating Scale and the Sheehan Disability Scale, edivoxetine showed superiority over placebo, with higher response and remission rates.

In December 2013, Eli Lilly announced that the clinical development of edivoxetine will be stopped due to lack of efficacy compared to SSRI alone in three separate clinical trials.

Side effects

Side effects significantly associated with edivoxetine are headache, nausea, constipation, dry mouth and insomnia.

The above-mentioned studies report increases of the cardiac rhythm, and one also increases of diastolic and systolic blood pressures.

See also

• Esreboxetine